Skip to content
GLP-1 Scorecard
Menu
Graded #44

Vaylen

Vaylen is a pure GLP-1 specialist offering compounded semaglutide ($179/mo), compounded tirzepatide ($239/mo), compounded oral GLP-1 ($259/mo), and brand-name Ozempic, Zepbound, and Wegovy.

Visit VaylenWe may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Semaglutide
$179/mo (compounded)
Tirzepatide
$239/mo (compounded)
Coverage
All 50 states
Brand-name
Yes

Weigh Vaylen against the full graded field on the best semaglutide providers scorecard, or line it up against its closest alternatives.

Factor breakdown

Each of the six graded dimensions. See the methodology.

Cost value66/100
Dose & formulation88/100
Clinical oversight84/100
Labs & monitoring77/100
Fulfillment90/100
Contract terms55/100

Strengths

  • Pure GLP-1 specialist — not a multi-category telehealth platform
  • All 50 states coverage with licensed clinicians
  • Both compounded and brand-name options (Ozempic, Wegovy, Zepbound)
  • Oral GLP-1 option (compounded dissolvable tablets) for needle-averse patients
  • LegitScript certified

Where it loses points

  • Compounded semaglutide at $179/mo is mid-range (not the cheapest)
  • Brand-name options at near-retail pricing ($997-$1,086/mo)

Bottom line — Grade C+

Best for: Shoppers who want gLP-1-focused care with oral and injectable options across all 50 states.

Ranked #44 of 499 on this scorecard. See our top-scoring pick, CoreAge Rx (#1), for comparison.

Closest on the board

The boards grading nearest Vaylen — the realistic shortlist.

The 21 boards nearest this one

View full scorecard rankings →

Pricing/verification reflect Vaylen's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on Vaylen's site. Not medical advice; see our disclosure.

← Back to the scorecard